These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19052001)

  • 21. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine.
    Setter SM; Neumiller JJ; Dobbins EK; Wood L; Clark J; DuVall CA; Santiago A
    Consult Pharm; 2009 Jul; 24(7):524-37. PubMed ID: 19689181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract]   [Full Text] [Related]  

  • 26. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.
    Frank S
    BMC Neurol; 2009 Dec; 9():62. PubMed ID: 20021666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deutetrabenazine in the treatment of Huntington's disease.
    Richard A; Frank S
    Neurodegener Dis Manag; 2019 Feb; 9(1):31-37. PubMed ID: 30624137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart Review.
    Claassen DO; Iyer RG; Shah-Manek B; DiBonaventura M; Abler V; Sung VW
    J Huntingtons Dis; 2018; 7(4):345-353. PubMed ID: 30282372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valbenazine in the treatment of tardive dyskinesia.
    Witek N; Comella C
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects.
    Stahl SM
    CNS Spectr; 2018 Feb; 23(1):1-6. PubMed ID: 29249207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe.
    Gopalakrishnan A; Sievert M; Ruoho AE
    Mol Pharmacol; 2007 Dec; 72(6):1567-75. PubMed ID: 17766642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM; Nicewonder JA
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
    Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
    Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetrabenazine: for chorea associated with Huntington's disease.
    Scott LJ
    CNS Drugs; 2011 Dec; 25(12):1073-85. PubMed ID: 22133328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
    Jankovic J; Clarence-Smith K
    Expert Rev Neurother; 2011 Nov; 11(11):1509-23. PubMed ID: 22014129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deutetrabenazine for Treatment of Chorea in Huntington Disease.
    Geschwind MD; Paras N
    JAMA; 2016 Jul; 316(1):33-5. PubMed ID: 27380339
    [No Abstract]   [Full Text] [Related]  

  • 37. Decreased platelet vesicular monoamine transporter density in habitual smokers.
    Schwartz K; Weizman A; Rehavi M
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):235-8. PubMed ID: 15695071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An experimental model for Huntington's chorea?
    Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y
    Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of tetrabenazine on the striatal uptake of exogenous L-DOPA in vivo: a PET study in young and aged rhesus monkeys.
    DeJesus OT; Shelton SE; Roberts AD; Nickles RJ; Holden JE
    Synapse; 2002 Jun; 44(4):246-51. PubMed ID: 11984859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
    Pidathala S; Liao S; Dai Y; Li X; Long C; Chang CL; Zhang Z; Lee CH
    Nature; 2023 Nov; 623(7989):1086-1092. PubMed ID: 37914936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.